A series of educational sessions will be held over a two week period.

PROGRAMME OVERVIEW

Monday 5th October
~ COVID-19 associated Acute Kidney Injury
   ~ Dialysis update – from COVID and into the future

Tuesday 6th October
~ Best clinical abstracts
~ New world of clinical trials how do we make it work

Wednesday 7th October
~ Improving Diabetes Care in Haemodialysis - Yes we can
~ Chronic kidney disease: redefining care

Thursday 8th October
~ Single cell ‘omics’ in renal disease research
~ Best Science abstracts

Friday 9th October
~ It’s Friday, 5pm and the phone goes

Tuesday 13th October
~ Right Time, Right Place, Right Role

Wednesday 14th October
~ UK Renal Registry – audit and research
~ Pathogenesis and treatment of glomerular disease and vasculitis

Thursday 15th October
~ Coping with Covid: Rising to the Challenge, Learning for the future.

Please see the programme details on page 3-8 for timings of the live educational sessions. As attendees view the live sessions, the platform will provide the opportunity for everyone to submit comments, feedback and questions directly to the presenters via live Q&A and discussion forums.
INTRODUCTION
In response to the global challenge, posed by the COVID-19 pandemic, UKKW will deliver a series of educational sessions using a virtual platform held over a two week period, starting on Monday 5th October, through to Thursday 15th October. The renal community has been at the forefront of the pandemic, and these events will also capture the experience and learnings during this time.

There will also be a virtual exhibition with the opportunity to meet industry representatives to discuss some of the latest devices and treatment options available, along with a poster hall.

We look forward to seeing you in October for an interesting and enjoyable conference.

REGISTRATION
UKKW would like to ensure this event is available for the whole renal team. We are also pleased to announce that Renal Departments can register all team members for just £100.

Additionally, individual registrations are available:

- Individual registration – £25
- Student – £15
- Patient – FoC
- Industry – £250

UKKW VIRTUAL
UKKW Virtual is a great opportunity to virtually meet and network with colleagues who share your enthusiasm for best practice in kidney care and renal science. The platform will open from 1200 hours on 5th October and close at 1900 hours on 15th October.

MEETING HUB
The virtual platform allows you to network with other attendees. By simply scrolling through attendees or using the advance search, you can see all attendees whom you can chat with or arrange instant face to face meetings at any time during the day.

POSTER GALLERY
In the poster hall is open to visit from 5th-15th October and will allow you to review abstracts, download posters and view any presentations that have been uploaded. You can also submit your questions directly to the author via the Q&A box.

SUPPORT
In order to log into the event platform we recommend that delegates use Google Chrome. Other browsers, such as Microsoft Edge, Firefox and Safari are also supported. Please ensure that you install a compliant browser prior to logging in. In addition, at any time during the conference support is available by clicking on the red live support icon at the top right hand side of the screen.

VIRTUAL RUN
UKKW are organising a virtual run. Take part on an individual basis, or enter a team to complete 26.2 miles during the time of the virtual conference. Further details are to follow.

SOCIAL MEDIA
Please use the following on social media #UKKW2020.
PROGRAMME

Monday 5th October

<table>
<thead>
<tr>
<th>1555-1628</th>
<th>16.30-17.30</th>
<th>17.30-17.45</th>
<th>17.45-18.45</th>
<th>18.45-19.30</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsored sessions</td>
<td>Session 1</td>
<td>Exhibition, posters, networking, comfort break</td>
<td>Dialysis update – from COVID and into the future</td>
<td>Exhibition, posters and networking</td>
</tr>
<tr>
<td>1555-1610 Vifor Pharma</td>
<td>COVID-19 associated Acute Kidney Injury</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chairs: Nick Selby and John Prowle</td>
<td>Introduction and overview of AKI in COVID-19 – Professor Nick Selby</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Causes of AKI in COVID-19 – is this a different disease? – Dr Chris Laing</td>
<td>Challenges and solutions when performing RRT in COVID-19 – Dr Marlies Ostermann</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adapting an acute dialysis service for a pandemic situation – Dr Smeeta Sinha</td>
<td>What are the long-term consequences of AKI in COVID-19? – Dr Kate Bramham</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interactive Q&amp;A – all speakers</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1613-1628 Presidents’ Welcome

Tuesday 6th October

<table>
<thead>
<tr>
<th>1613-1628</th>
<th>16.30-17.30</th>
<th>17.30-17.45</th>
<th>17.45-18.45</th>
<th>18.45-19.30</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsored session</td>
<td>Session 1</td>
<td>Exhibition, posters, networking, comfort break</td>
<td>Clinical Trials – Generating Evidence to Advance Care</td>
<td>Exhibition, posters and networking</td>
</tr>
<tr>
<td>1613-1628</td>
<td>Best clinical abstracts</td>
<td></td>
<td>Chair: Thomas Hiemstra</td>
<td></td>
</tr>
<tr>
<td>Chairs: Sally Johnson and Aisling McMahon</td>
<td></td>
<td></td>
<td>The RECOVERY Trial – Professor Richard Haynes</td>
<td></td>
</tr>
<tr>
<td>• 62 - Stable calcium isotopes: a novel biomarker of bone mineralisation in</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Exhibition, posters and networking
children with chronic kidney disease – Dr Rukshana Shroff

• 163 - A randomized, controlled trial of rituximab versus azathioprine after induction of remission with rituximab for patients with ANCA-associated vasculitis and relapsing disease – Dr Rona Smith

• 584 - The PrEscription of intraDialytic exercise to improve quAlity of Life (PEDAL) in patients with chronic kidney disease trial: A multi-centre randomised controlled trial – Dr Sharlene Greenwood

• 9 - Kidney transplant outcomes for children and young adults in the UK – Dr Alexander Hamilton

• 396 - Major Adverse Cardiovascular Events (MACE) after kidney transplantation: a population-cohort analysis of English transplant centres – Dr Benjamin Anderson

• 149 - Associations with peritoneal dialysis treatment failure for children and young adults in the UK – Dr Alexander Hamilton

Top Line results from the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD study) – Professor David Wheeler on behalf of the DAPA-CKD Trials Committees and Investigators

Results from the Paclitaxel-coated balloons and angioplasty of arteriovenous fistulas (PAVE) trial – Dr Mike Robson

Wednesday 7th October

1555-1628  
Sponsored sessions

| 1555-1610 | Improving Diabetes Care in Haemodialysis – Yes we can |
| Napp Sponsored Session | Chairs: Apexa Kuverji and Jo Reed |

| 1613-1628 | Chronic kidney disease: redefining care |
| Vifor Pharma Sponsored Session | Chairs: Sue Shaw and Mark Jesky |

16.30-17.30  
Session 1

| 17.30-17.45 | Exhibition, posters, networking, comfort break |

17.30-18.45  
Session 2

| 18.45-19.30 | Exhibition, posters and networking |

DiH why, what and how – Dr James Burton

SGLT-2 inhibitors – the current status: Professor Maarten Taal
### Thursday 8th October

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 1</th>
<th>Session 2</th>
<th>Exhibition, posters, networking, comfort break</th>
<th>Best Science abstracts</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.30-17.30</td>
<td>Single cell ‘omics’ in renal disease research</td>
<td>Exhibition, posters, networking, comfort break</td>
<td>Chairs: Gavin Welsh</td>
<td>280 - Sirt5 deletion protects from ischaemic AKI and enhances nephrotoxic CKD – Timo Hascheler</td>
</tr>
<tr>
<td></td>
<td>Chairs: Gavin Welsh</td>
<td></td>
<td></td>
<td>360 - Endothelial glycocalyx heparan sulphate plays a key role in glomerular barrier function in health and is amenable to therapeutic targeting in diabetes – Dr Monica Gamez</td>
</tr>
<tr>
<td></td>
<td>Human Kidney Cell Atlas - Applications for nephrology and transplantation – Professor Menna Clatworthy</td>
<td></td>
<td></td>
<td>370 - Dapagliflozin inhibition of non-canonical Smad signalling prevents fibrotic outcomes in diabetic kidney disease – Xinlu Pan</td>
</tr>
<tr>
<td></td>
<td>Podocyte ‘omics’ identifies novel signalling pathways in albuminuria kidney disease – Professor Richard Coward</td>
<td></td>
<td></td>
<td>390 - Glomerular microRNAs are primary instigators of Diabetic Nephropathy – Dr Alexa Wonnacott</td>
</tr>
<tr>
<td>17.30-17.45</td>
<td>4.02 - Kidney single-cell atlas reveals myeloid heterogeneity in progression and regression of kidney disease – Eoin O’Sullivan</td>
<td></td>
<td></td>
<td>463 - Mineralocorticoid receptor blockade preserves the glomerular endothelial glycocalyx and normalises glomerular permeability in diabetic nephropathy – Dr Michael Crompton</td>
</tr>
<tr>
<td>17.45-18.45</td>
<td>409 - Renal epithelial senescence drives post injury fibrosis – Eoin O’Sullivan</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18.45-19.30</td>
<td>1613-1628 Sponsored session</td>
<td>1613-1628 Sponsored session</td>
<td></td>
<td>401 - Mineralocorticoid receptor blockade preserves the glomerular endothelial glycocalyx and normalises glomerular permeability in diabetic nephropathy – Dr Michael Crompton</td>
</tr>
</tbody>
</table>

#### Programme continued

- How the Dietitian can improve the diabetes care for people with diabetes on HDx – TBC
  - Monitoring glycaemia for people with diabetes on haemodialysis – pitfalls and solutions – Dr Tahseen Chowdhury
  - Q&A – 10 minutes
- The role of the pharmacist in the primary and secondary care management of CKD – Clare Morlidge
  - Virtual CKD clinics; Covid and beyond – Gavin Dreyer
  - Can electronic patient reported outcomes define patient initiated follow-up – Sabine van der Veer

**Sponsored Session**

- Single cell ‘omics’ in renal disease research
- Human Kidney Cell Atlas - Applications for nephrology and transplantation – Professor Menna Clatworthy
- Podocyte ‘omics’ identifies novel signalling pathways in albuminuria kidney disease – Professor Richard Coward
- 128 - Single nucleus RNA sequencing identifies new classes of renal proximal tubular epithelial cell in a chronic renal fibrosis model – Yeuh-An Lu
- 402 - Kidney single-cell atlas reveals myeloid heterogeneity in progression and regression of kidney disease – Eoin O’Sullivan
- 409 - Renal epithelial senescence drives post injury fibrosis – Eoin O’Sullivan
PROGRAMME continued

- **418** - Single cell RNA sequencing of immune cells in models of acute kidney injury and chronic renal fibrosis – Dr Bnar Talabani

- **483** - Identification of differentially methylated genes in individuals with end-stage kidney disease attributed to diabetic kidney disease – Dr Laura Smyth

**Friday 9th October**

**16.30-18.00**

*Its Friday, 5pm and the phone goes*

Chair: Lynne Sykes and Marie Condon

Antibody Mediated Rejection – Michelle Willicombe

Hepatorenal syndrome – Professor Andrew Davenport

Cardiorenal syndrome - Professor Phil Kalra

**Tuesday 13th October**

**16.30-18.30**

Right Time, Right Place, Right Role

Chair: Ellen Castle and Helen Hurst

**PART ONE: The 2020 Work Force Planning Document Launch**

Chairs welcome and intro

a) Where we started and where we are now; work force planning – Hannah Young

b) Key learnings from the whole MDT

c) Commissioning and work force making it meaningful for all – TBC

d) Commissioners perspective-seeing it at as a whole! – Ian Wren

e) GIRFT -Why the work force matters – Dr Graham Lipkin

f) Q and A panel with all speakers

**PART TWO: Changes in workforce during COVID**

a) Changes to the medic work force – Sunil Bandari

b) Changes to the ART workforce – Roger Moore

c) and d) changes to the therapy workforce – Juliet Mayes and Dr Sharlene Greenwood

e) The leadership conundrum in COVID – Steve Andrews

f) Working towards the future – Karen Jenkins

g) Q and A with all speakers

16.30-18.30

18.30-19.15

Exhibition, posters and networking
### Wednesday 14th October

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 1</th>
<th>Session 2</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.30-17.30</td>
<td>UK Renal Registry – audit and research</td>
<td>Pathogenesis and treatment of glomerular disease and vasculitis</td>
<td>18.45-19.30</td>
</tr>
<tr>
<td>17.30-17.45</td>
<td>Chairs: Ron Cullen and Fran Benoy-Deeney</td>
<td>Chair: Sally Hamour</td>
<td></td>
</tr>
<tr>
<td>17.45-18.45</td>
<td>Chairs welcome to the session</td>
<td>• 544 - Peripheral T helper cells may play a significant role in the pathogenesis of ANCA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Introduction &amp; overview – Dr Retha Steenkamp, Professor James Medcalf and</td>
<td>associated vasculitis – Dr Seerapani</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Professor Dorothea Nitsch</td>
<td>• 292 - Neutrophils are required for anti-myeloperoxidase antibody vasculitis but inhibition</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Epidemiology of COVID-19 across RRT modalities – Dr Manuela Savino</td>
<td>of myeloperoxidase does not affect disease – Dr Fernanda Florez-barros</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AKI in a national cohort of children: epidemiology and outcomes using linked</td>
<td>• 59 - The safety profile of repeat rituximab treatment in ANCA-associated vasculitis –</td>
<td></td>
</tr>
<tr>
<td></td>
<td>electronic health data – Dr Lucy Plumb</td>
<td>a 10 year single centre study – Dr Pek Ghe Tan</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Patient transitions between KRT, CKD and AKI datasets at the UK Renal</td>
<td>• 567 - Long term maintenance rituximab for ANCA-associated vasculitis: infection and</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Registry – Dr Barnaby Hole</td>
<td>relapse prediction models – Dr Mark Mcclure</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Working with the UK Renal Registry – Dr Katharine Evans and Tom Gray</td>
<td>• 415 - Treatment of adult patients with relapsing Minimal Change Disease with targeted B</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Q&amp;A session</td>
<td>cell depletion – Dr Rakesh Dattani</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 428 - Contactin-1 is a novel antigen in primary membranous glomerulonephritis (MGN) and</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>in CIDP-associated MGN – Professor Alan Salama</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 374 - Five and Ten Year Outcomes of a Large Cohort of Patients with Membranous Nephropathy</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>treated with Tacrolimus – Lina Nikolopoulou</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 259 - Strategies for Reduction of Cardiovascular Risk: Effect of Time and Different</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Treatments on Lipids in Membranous Nephropathy – Dr Thomas Oates</td>
<td></td>
</tr>
</tbody>
</table>

### Exhibition, posters, networking

- **1613-1628**
  - **Sponsored session**
  - **16.30-17.30**
  - **Session 1**
  - **17.30-17.45**
  - **Session 2**
  - **17.45-18.45**
  - **18.45-19.30**

Programme.qxp_Layout 1  28/08/2020  14:03  Page 5
Coping with Covid: Rising to the Challenge, Learning for the future.   
Chairs: Fiona Loud and Nicki Thomas

How we responded
Response of the professional community – Paul Cockwell
Response for and with patients – Fiona Loud

What we learnt and put in place
The experience of staff working in a highly affected inner city satellite unit of Tottenham Hale – Tara Baptiste
Caring for the carers: the impact of COVID on mental health of staff, support for staff as the clapping stops – Janette Moran
What was the true cost to patients? The Kidney Care UK Survey results – Nicholas Palmer
Supporting the effect on mental health in patients – Dee Durham (TBC)
The experience of younger patients in the COVID19 using the Share: Survey results of the impact of COVID19 on younger people with kidney disease Young adult speaker – TBC
When your risks are high due to your ethnicity: patient experience of COVID19 – Belinda Otas

Planning for the future
After Shielding: mechanisms to support the most at risk – Katie Vinen (TBC)
Planning for future: estates and unit design with pandemic in mind – Rosie Donne (TBC)
How to manage general nephrology patients who require immunosuppression – Liz Lightstone (TBC)

Panel discussion
FOR FURTHER INFORMATION PLEASE CONTACT

UKKW c/o Executive Business Support Ltd
City Wharf, Davidson Road Lichfield
Staffordshire, WS14 9DZ
United Kingdom
Tel: 01543 442 192
E-mail: info@ukkw.org.uk
Website: www.ukkw.org.uk